Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research · Oct 8, 2026
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DCPRNewsWire · Aug 20, 2026
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, SpainPRNewsWire · Aug 18, 2026
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault LendingPRNewsWire · Aug 4, 2026Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 10, 2026 | -$0.56 | -$0.68 | Miss |
| Jul 22, 2026 | -$0.67 | -$0.74 | Miss |
| Mar 11, 2026 | -$0.53 | -$0.58 | Miss |
| Dec 9, 2025 | -$0.83 | -$0.30 | Beat |
| Sep 10, 2025 | -$3.69 | -$1.28 | Beat |
| Jul 29, 2025 | -$2.70 | -$2.36 | Beat |